Lupin Limited
LUPIN
Rank in Stocks
#2103
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
Share Price
$21.40
Last synced: 2026-10-19
Market Cap
$9.79B
Change (1 day)
-1.36%
Change (1 year)
-3.25%
Country
IN
Trade Lupin Limited (LUPIN)
Category
Healthcare
P/S ratio for Lupin Limited (LUPIN)
P/S ratio as of October 2026 TTM: 3.02
According to Lupin Limited latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.02. At the end of 2024 the company had a P/S ratio of 3.71.
P/S ratio history for Lupin Limited from 2004 to 2026
P/S ratio at the end of each year
| Year | P/S Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.02 | -23.28% |
| 2025 | 3.94 | 6.24% |
| 2024 | 3.71 | 107.54% |
| 2023 | 1.79 | -13.98% |
| 2022 | 2.08 | -32.49% |
| 2021 | 3.08 | 74.64% |
| 2020 | 1.76 | -27.16% |
| 2019 | 2.42 | 7.19% |
| 2018 | 2.26 | -41.15% |
| 2017 | 3.84 | -21.44% |
| 2016 | 4.88 | -31.82% |
| 2015 | 7.16 | 90.00% |
| 2014 | 3.77 | 25.69% |
| 2013 | 3.00 | -10.14% |
| 2012 | 3.34 | 2.60% |
| 2011 | 3.25 | 10.85% |
| 2010 | 2.93 | 96.35% |
| 2009 | 1.49 | -0.60% |
| 2008 | 1.50 | -37.81% |
| 2007 | 2.42 | 0.70% |
| 2006 | 2.40 | 37.87% |
| 2005 | 1.74 | -18.90% |
| 2004 | 2.15 | 0.00% |
P/S ratio for similar companies or competitors
| Company | P/S Ratio | P/S Ratio Difference | Country |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | 133.50% |
IN
|
